File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis

TitleEffect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis
Authors
Keywordsatrial natriuretic peptide
chronic renal failure
continuous ambulatory peritoneal dialysis
endothelin
hypertension
renin activity
Issue Date1991
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/NEF
Citation
Nephron, 1991, v. 57 n. 4, p. 394-400 How to Cite?
AbstractThe effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin (rHuEPO) on blood pressure was evaluated in 20 patients with renal failure on continuous ambulatory peritoneal dialysis. The two groups of patients were commenced on a 16-week course of twice weekly rHuEPO by either the subcutaneous (10 patients) or the intraperitoneal route (10 patients). One patient in the latter group was subsequently excluded because of operation and transfusion. The hemoglobulin increased significantly from 6.9 ± 0.3 g/dl to 9.8 ± 0.6 g/dl after subcutaneous rHuEPO treatment (p < 0.01) at an average dose of 84 ± 9 U/kg body weight/week. For the intraperitoneal group, despite a higher average rHuEPO dosage (133 ± 7 U/kg body weight/week), the hemoglobin level was not significantly altered (7.0 ± 0.4 g/dl to 8.0 ± 0.4 g/dl, p < 0.03). During the 16-week period of rHuEPO therapy, an increase in antihypertensive therapy was required more frequently in patients in the intraperitoneal group but the difference between groups failed to reach statistical significance. There was no conclusive evidence that the rise in hematocrit was an independent precipitant of hypertension. Patients who were hypertensive prior to rHuEPO therapy appeared most susceptible to the pressor effects in that 8 of 11 treated hypertensive patients required more intensive antihypertensive treatment during EPO administration whereas none of the untreated patients developed hypertension during the study (Fisher's exact test, p = 0.007). Plasma levels of the vasoactive hormones, atrial natriuretic peptide (ANP), plasma renin activity (PRA), and endothelin (ET) remained unchanged during both subcutaneous and intraperitoneal rHuEPO therapy. These observations suggest that the presence of hypertension predisposes to the pressor effect of EPO, and that the vasoactive hormones ANP, PRA, and ET are unlikely to be involved in the pathophysiology of rHuEPO-induced hypertension.
Persistent Identifierhttp://hdl.handle.net/10722/161864
ISSN
2004 Impact Factor: 1.462
2006 SCImago Journal Rankings: 0.715
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, KNen_HK
dc.contributor.authorLui, SFen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorLaw, Een_HK
dc.contributor.authorNicholls, MGen_HK
dc.date.accessioned2012-09-05T05:15:35Z-
dc.date.available2012-09-05T05:15:35Z-
dc.date.issued1991en_HK
dc.identifier.citationNephron, 1991, v. 57 n. 4, p. 394-400en_HK
dc.identifier.issn0028-2766en_HK
dc.identifier.urihttp://hdl.handle.net/10722/161864-
dc.description.abstractThe effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin (rHuEPO) on blood pressure was evaluated in 20 patients with renal failure on continuous ambulatory peritoneal dialysis. The two groups of patients were commenced on a 16-week course of twice weekly rHuEPO by either the subcutaneous (10 patients) or the intraperitoneal route (10 patients). One patient in the latter group was subsequently excluded because of operation and transfusion. The hemoglobulin increased significantly from 6.9 ± 0.3 g/dl to 9.8 ± 0.6 g/dl after subcutaneous rHuEPO treatment (p < 0.01) at an average dose of 84 ± 9 U/kg body weight/week. For the intraperitoneal group, despite a higher average rHuEPO dosage (133 ± 7 U/kg body weight/week), the hemoglobin level was not significantly altered (7.0 ± 0.4 g/dl to 8.0 ± 0.4 g/dl, p < 0.03). During the 16-week period of rHuEPO therapy, an increase in antihypertensive therapy was required more frequently in patients in the intraperitoneal group but the difference between groups failed to reach statistical significance. There was no conclusive evidence that the rise in hematocrit was an independent precipitant of hypertension. Patients who were hypertensive prior to rHuEPO therapy appeared most susceptible to the pressor effects in that 8 of 11 treated hypertensive patients required more intensive antihypertensive treatment during EPO administration whereas none of the untreated patients developed hypertension during the study (Fisher's exact test, p = 0.007). Plasma levels of the vasoactive hormones, atrial natriuretic peptide (ANP), plasma renin activity (PRA), and endothelin (ET) remained unchanged during both subcutaneous and intraperitoneal rHuEPO therapy. These observations suggest that the presence of hypertension predisposes to the pressor effect of EPO, and that the vasoactive hormones ANP, PRA, and ET are unlikely to be involved in the pathophysiology of rHuEPO-induced hypertension.en_HK
dc.languageengen_US
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/NEFen_HK
dc.relation.ispartofNephronen_HK
dc.subjectatrial natriuretic peptideen_HK
dc.subjectchronic renal failureen_HK
dc.subjectcontinuous ambulatory peritoneal dialysisen_HK
dc.subjectendothelinen_HK
dc.subjecthypertensionen_HK
dc.subjectrenin activityen_HK
dc.subject.meshAdulten_US
dc.subject.meshAtrial Natriuretic Factor - Blooden_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshEndothelins - Blooden_US
dc.subject.meshErythropoietin - Administration & Dosage - Pharmacology - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHemoglobins - Analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshHypertension - Blood - Drug Therapy - Physiopathologyen_US
dc.subject.meshInjections, Intraperitonealen_US
dc.subject.meshInjections, Subcutaneousen_US
dc.subject.meshKidney Failure, Chronic - Physiopathology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeritoneal Dialysis, Continuous Ambulatoryen_US
dc.subject.meshRecombinant Proteins - Administration & Dosage - Pharmacology - Therapeutic Useen_US
dc.subject.meshRenin - Blooden_US
dc.subject.meshTime Factorsen_US
dc.titleEffect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysisen_HK
dc.typeArticleen_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1159/000186302-
dc.identifier.pmid1828543-
dc.identifier.scopuseid_2-s2.0-0025772045en_HK
dc.identifier.volume57en_HK
dc.identifier.issue4en_HK
dc.identifier.spage394en_HK
dc.identifier.epage400en_HK
dc.identifier.isiWOS:A1991FC97400002-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridLui, SF=55066056500en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridLaw, E=7102359026en_HK
dc.identifier.scopusauthoridNicholls, MG=7202358024en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats